As of 2026-09-29, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (9.79) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.47 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -215.5%.
The range of the Relative Valuation is (36.75) - 30.24 USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 24.3x - 37.4x | 28.1x |
| Forward P/E multiples | 14.6x - 26.9x | 20.4x |
| Fair Price | (36.75) - 30.24 | (9.79) |
| Upside | -533.9% - 257.1% | -215.5% |
| Date | P/E |
| 2026-09-25 | -5.68 |
| 2026-09-24 | -5.63 |
| 2026-09-23 | -5.66 |
| 2026-09-22 | -5.80 |
| 2026-09-21 | -5.79 |
| 2026-09-18 | -5.74 |
| 2026-09-17 | -5.75 |
| 2026-09-16 | -5.57 |
| 2026-09-15 | -5.39 |
| 2026-09-14 | -5.44 |
| 2026-09-11 | -5.37 |
| 2026-09-10 | -5.48 |
| 2026-09-09 | -5.82 |
| 2026-09-08 | -5.99 |
| 2026-09-04 | -6.58 |
| 2026-09-03 | -6.67 |
| 2026-09-02 | -6.72 |
| 2026-09-01 | -6.55 |
| 2026-08-31 | -6.41 |
| 2026-08-28 | -6.49 |
| 2026-08-27 | -6.52 |
| 2026-08-26 | -6.49 |
| 2026-08-25 | -6.49 |
| 2026-08-24 | -6.40 |
| 2026-08-21 | -6.31 |
| 2026-08-20 | -6.38 |
| 2026-08-19 | -6.65 |
| 2026-08-18 | -6.41 |
| 2026-08-17 | -6.57 |
| 2026-08-14 | -6.44 |
| 2026-08-13 | -6.48 |
| 2026-08-12 | -7.00 |
| 2026-08-11 | -6.83 |
| 2026-08-10 | -6.50 |
| 2026-08-07 | -6.20 |
| 2026-08-06 | -6.14 |
| 2026-08-05 | -5.99 |
| 2026-08-04 | -5.96 |
| 2026-08-03 | -5.82 |
| 2026-07-31 | -5.93 |
| 2026-07-30 | -6.11 |
| 2026-07-29 | -6.30 |
| 2026-07-28 | -6.44 |
| 2026-07-27 | -6.33 |
| 2026-07-24 | -6.17 |
| 2026-07-23 | -6.20 |
| 2026-07-22 | -6.28 |
| 2026-07-21 | -6.22 |
| 2026-07-20 | -6.02 |
| 2026-07-17 | -6.14 |